 |
Top 10 ALS startups
Updated: April 19, 2024 |
These startups develop new ALS treatments and diagnostics technologies, like AI-powered imaging and drug-discovery, gene therapy, stem cells, communication apps and gadgets.
1
Country: USA | Funding: $622M
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
2
Country: USA | Funding: $509M
Annexon Biosciences a biotechnology company, discovers and developing novel therapeutics for neurodegenerative and autoimmune disorders.
Annexon Biosciences a biotechnology company, discovers and developing novel therapeutics for neurodegenerative and autoimmune disorders.
3
Country: USA | Funding: $448.5M
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
4
Country: USA | Funding: $374M
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
5
Country: USA | Funding: $181.2M
Skyhawk's is developing small molecule therapeutics that correct RNA expression.Their proprietary technology enables the rational design of small molecules that target the RNA splicing process.They are now developing drug candidates for cancer, neurological disease, and rare disease.
Skyhawk's is developing small molecule therapeutics that correct RNA expression.Their proprietary technology enables the rational design of small molecules that target the RNA splicing process.They are now developing drug candidates for cancer, neurological disease, and rare disease.
6
Country: Netherlands | Funding: €160M
VectorY Therapeutics develops gene therapies against amyotrophic lateral sclerosis (ALS) and Alzhiemer’s disease.
VectorY Therapeutics develops gene therapies against amyotrophic lateral sclerosis (ALS) and Alzhiemer’s disease.
7
Country: Australia | Funding: $145M
Synchron manufactures and markets a medical device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic.
Synchron manufactures and markets a medical device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic.
8
Country: USA | Funding: $137.4M
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
9
Country: USA | Funding: $135.5M
QurAlis is specifically focused on discovering & developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease.
QurAlis is specifically focused on discovering & developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease.
10
Country: USA | Funding: $134.1M
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
11
Country: Israel | Funding: $59.1M
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
12
Country: Israel | Funding: $20M
NeuroSense Therapeutics is a clinical stage drug development company offering ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases. Focused on a combined therapy, targeting multiple pertinent MoAs in these complex diseases.
NeuroSense Therapeutics is a clinical stage drug development company offering ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases. Focused on a combined therapy, targeting multiple pertinent MoAs in these complex diseases.
13
Country: Israel | Funding: $15.3M
EyeControl is a new solution for locked in patients, that allows them to communicate using eye movements only. Based on a new technology, EyeControl will be a Low Cost solution approachable for any ALS patient.
EyeControl is a new solution for locked in patients, that allows them to communicate using eye movements only. Based on a new technology, EyeControl will be a Low Cost solution approachable for any ALS patient.
14
Country: USA | Funding: $10.5M
AxoSim's Nerve-on-a-Chip platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
AxoSim's Nerve-on-a-Chip platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
15
Country: USA
Iron Horse Therapeutics is developing treatments for amyotrophic lateral sclerosis (ALS) with compounds that modulate the activity of EphA4. Humans with EphA4 mutations that decrease its activity or reduced EphA4 expression levels exhibit prolonged survival and reduced disease severity. Similar results have been demonstrated in ALS mouse and rat animal models.
Iron Horse Therapeutics is developing treatments for amyotrophic lateral sclerosis (ALS) with compounds that modulate the activity of EphA4. Humans with EphA4 mutations that decrease its activity or reduced EphA4 expression levels exhibit prolonged survival and reduced disease severity. Similar results have been demonstrated in ALS mouse and rat animal models.
16
Country: USA | Funding: $4M
CavoGene LifeSciences develops a novel gene therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS), colloquially known as Lou Gherig's disease, and other forms of neurodegeneration.
CavoGene LifeSciences develops a novel gene therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS), colloquially known as Lou Gherig's disease, and other forms of neurodegeneration.
17
Country: Israel | Funding: $2.5M
Umoove is the first ever, pure software, face and eye tracking, for any mobile device. No extra hardware needed. A unique technology, built from ground up, that has attracted the attention of many of the biggest companies in the world.
Umoove is the first ever, pure software, face and eye tracking, for any mobile device. No extra hardware needed. A unique technology, built from ground up, that has attracted the attention of many of the biggest companies in the world.
18
Country: USA | Funding: $120K
A bioinformatics company offering a unique platform for crowd-sourced brain research. It leverages cloud computing, big data and mobile technology to offer valuable personal insights and accelerate brain research globally.
A bioinformatics company offering a unique platform for crowd-sourced brain research. It leverages cloud computing, big data and mobile technology to offer valuable personal insights and accelerate brain research globally.
19
Country: Germany
Priavoid envisions curing neurological disorders by developing innovative treatment strategies based on a new class of orally available compounds. Focusing on indications with significant unmet medical need Priavoid applies the therapeutic concept to Alzheimer’s disease (AD), neuropathic pain and other neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), tauopathies, Parkinson’s disease (PD), and Huntington’s disease (HD).
Priavoid envisions curing neurological disorders by developing innovative treatment strategies based on a new class of orally available compounds. Focusing on indications with significant unmet medical need Priavoid applies the therapeutic concept to Alzheimer’s disease (AD), neuropathic pain and other neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), tauopathies, Parkinson’s disease (PD), and Huntington’s disease (HD).